Abstract
Medulloblastoma, a highly cellular malignant embryonal neoplasm classified as a primitive neuroectodermal tumor (PNET) [1], is the most common malignant brain tumor in children, accounting for 15–25% of all childhood primary central nervous system (CNS) neoplasms [2]. By definition, medulloblastoma arises in the posterior fossa, usually from the cerebellar vermis in the roof of the fourth ventricle (Fig. 18.1). Medulloblastomas have a marked tendency to spread by seeding along the cerebrospinal fluid (CSF) pathways; evidence of this metastatic process is found in up to 35% of cases at diagnosis
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Kleihues P, Burger PC, Scheithauer BW. Histological typing of tumors of the central nervous system. WHO International Histological Classification of Tumors. 2nd ed. New York, Tokyo: Springer; 1993.
Peris-Bonet R, Martinez-Garcia C, Lacour B et al. Childhood central nervous system tumours – incidence and survival in Europe (1978–1997): report from Automated Childhood Cancer Information System Project. Eur J Cancer. 2006;42:2064–80.
Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents. Vol. VIII. Lyon: International Agency for Research on Cancer; 2002. IARC Scient. Publ. No. 155.
Verdecchia A, Francisci S, Brenner H et al. Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007;8:784–96.
Stewart BW, Kleihus P, editors. World cancer report. Lyon: IARC Press. 2003.
Shore RE, Moseson M, Harley N, Pasternack BS. Tumors and other diseases following childhood X-ray treatment for ringworm of the scalp (Tinea capitis). Health Phys. 2003;85:404–8.
Croul S, Otte J, Khalili K. Brain tumors and polyomaviruses. J Neurovirol. 2003;9:173–82.
Buhren J, Christoph AH, Buslei R et al. Expression of the neurotrophin receptor p75NTR in medulloblastomas is correlated with distinct histological and clinical features: evidence for a medulloblastoma subtype derived from the external granule cell layer. J Neuropathol Exp Neurol. 2000;59:229–40.
Pietsch T, Waha A, Koch A et al. Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res. 1997;57:2085–8.
Sarkar C, Pramanik P, Karak AK et al. Are childhood and adult medulloblastomas different? A comparative study of clinicopathological features, proliferation index and apoptotic index. J Neurooncol. 2002;59:49–61.
Herms J, Neidt I, Luscher B et al. C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer. 2000;%20 89:395–402.
Grotzer MA, Hogarty MD, Janss AJ et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res. 2001;7:2425–33.
Batra SK, McLendon RE, Koo JS et al. Prognostic implications of chromosome 17p deletions in human medulloblastomas. J Neurooncol. 1995;24:39–45.
Biegel JA, Janss AJ, Raffel C et al. Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumors (medulloblastomas) of the central nervous system. Clin Cancer Res. 1997;3:473–8.
Cogen PH, McDonald JD. Tumor suppressor genes and medulloblastoma. J Neurooncol. 1996;29:103–12.
Brandes AA, Ermani M, Amista P et al. The treatment of adults with medulloblastoma: a prospective study. Int J Radiat Oncol Biol Phys. 2003;57:755–61.
Schofield D, West DC, Anthony DC, Marshal R, Sklar J. Correlation of loss of heterozygosity at chromosome 9q with histological subtype in medulloblastomas. Am J Pathol. 1995;146:472–80.
Rudin CM, Hann CL, Laterra J et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;361:1173–8.
Frost PJ, Laperriere NJ, Wong CS et al. Medulloblastoma in adults. Int J Radiat Oncol Biol Phys. 1995;32:951–7.
Carrie C, Lasset C, Alapetite C et al. Multivariate analysis of prognostic factors in adult patients with medulloblastoma. Retrospective study of 156 patients. Cancer 1994;74:2352–60.
Chan AW, Tarbell NJ, Black PM et al. Adult medulloblastoma: prognostic factors and patterns of relapse. Neurosurgery 2000;47:623–31.
Rochkind S, Blatt I, Sadeh M, Goldhammer Y. Extracranial metastases of medulloblastoma in adults: literature review. J Neurol Neurosurg Psychiatry. 1991;54:80–6.
Ray A, Ho M, Ma J et al. A clinicobiological model predicting survival in medulloblastoma. Clin Cancer Res. 2004;10:7613–20.
Pomeroy SL, Tamayo P, Gaasenbeek M et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002;415:436–42.
Packer RJ, Rood BR, MacDonald TJ. Medulloblastoma: present concepts of stratification into risk groups. Pediatr Neurosurg. 2003;39:60–7.
Tabori U, Sung L, Hukin J et al. Distinctive clinical course and pattern of relapse in adolescents with medulloblastoma. Int J Radiat Oncol Biol Phys. 2006;64:402–7.
Prados MD, Warnick RE, Wara WM et al. Medulloblastoma in adults. Int J Radiat Oncol Biol Phys. 1995;32:1145–52.
Brandes AA, Franceschi E, Tosoni A, Blatt V, Ermani M. Long-term results of a prospective study on the treatment of medulloblastoma in adults. Cancer 2007;110:2035–41.
Padovani L, Sunyach MP, Perol D et al. Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults. Int J Radiat Oncol Biol Phys. 2007;68:433–40.
Cohen BH, Packer RJ. Chemotherapy for medulloblastomas and primitive neuroectodermal tumors. J Neurooncol. 1996;29:55–68.
Timmermann B, Kortmann RD, Kuhl J et al. Role of radiotherapy in the treatment of supratentorial primitive neuroectodermal tumors in childhood: results of the prospective German brain tumor trials HIT 88/89 and 91. J Clin Oncol. 2002;20:842–9.
Halperin EC, Friedman HS, Schold SC Jr. et al. Surgery, hyperfractionated craniospinal irradiation, and adjuvant chemotherapy in the management of supratentorial embryonal neuroepithelial neoplasms in children. Surg Neurol. 1993;40:278–83.
Kortmann RD, Kuhl J, Timmermann B et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT’91. Int J Radiat Oncol Biol Phys. 2000;46:269–79.
Tomita T. Neurosurgical perspectives in pediatric neurooncology. Childs Nerv Syst. 1998;14:94–6.
Albright AL, Wisoff JH, Zeltzer PM et al. Effects of medulloblastoma resections on outcome in children: a report from the Children’s Cancer Group. Neurosurgery 1996;38:265–71.
Cushing H. Experiences with cerebellar astrocytoma. A critical review. Acta Pathol Microbiol Scand. 1930;7:1–86.
Paterson E, Farr RF. Cerebellar medulloblastoma: treatment by radiation of the whole central nervous system. Acta Radiologica. 1953;39:323–36.
Hubbard JL, Scheithauer BW, Kispert DB et al. Adult cerebellar medulloblastomas: the pathological, radiographic, and clinical disease spectrum. J Neurosurg. 1989;70:536–44.
Ferrante L, Mastronardi L, Celli P et al. Medulloblastoma in adulthood. J Neurosurg Sci. 1991;35:23–30.
Bloom HJ, Bessell EM. Medulloblastoma in adults: a review of 47 patients treated between 1952 and 1981. Int J Radiat Oncol Biol Phys. 1990;18:763–72.
Berry MP, Jenkin RD, Keen CW, Nair BD, Simpson WJ. Radiation treatment for medulloblastoma. A 21-year review. J Neurosurg. 1981;55:43–51.
Kortmann RD, Kuhl J, Timmermann B et al. [Current and future strategies in interdisciplinary treatment of medulloblastomas, supratentorial PNET (primitive neuroectodermal tumors) and intracranial germ cell tumors in childhood]. Strahlenther Onkol. 2001;177:447–61.
Hazuka MB, DeBiose DA, Henderson RH, Kinzie JJ. Survival results in adult patients treated for medulloblastoma. Cancer 1992;69:2143–8.
Abacioglu U, Uzel O, Sengoz M, Turkan S, Ober A. Medulloblastoma in adults: treatment results and prognostic factors. Int J Radiat Oncol Biol Phys. 2002;54:855–60.
Thomas PR, Deutsch M, Kepner JL et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol. 2000;18:3004–11.
Packer RJ, Goldwein J, Nicholson HS et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children’s Cancer Group Study. J Clin Oncol. 1999;17:2127–36.
Packer RJ, Gajjar A, Vezina G et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24:4202–8.
Carrie C, Muracciole X, Gomez F et al. Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy, and online quality control in standard-risk medulloblastoma without chemotherapy: results of the French M-SFOP 98 protocol. Int J Radiat Oncol Biol Phys. 2005;63:711–6.
Tabori U, Sung L, Hukin J et al. Medulloblastoma in the second decade of life: a specific group with respect to toxicity and management: a Canadian Pediatric Brain Tumor Consortium Study. Cancer 2005;103:1874–80.
Greenberg HS, Chamberlain MC, Glantz MJ, Wang S. Adult medulloblastoma: multiagent chemotherapy. Neuro-oncol 2001;3:29–34.
Grabenbauer GG, Beck JD, Erhardt J et al. Postoperative radiotherapy of medulloblastoma. Impact of radiation quality on treatment outcome. Am J Clin Oncol. 1996;19:73–7.
Miralbell R, Bleher A, Huguenin P et al. Pediatric medulloblastoma: radiation treatment technique and patterns of failure. Int J Radiat Oncol Biol Phys. 1997;37:523–9.
Carrie C, Hoffstetter S, Gomez F et al. Impact of targeting deviations on outcome in medulloblastoma: study of the French Society of Pediatric Oncology (SFOP). Int J Radiat Oncol Biol Phys. 1999;45:435–9.
Kortmann RD, Timmermann B, Kuhl J et al. HIT’91 (prospective, co-operative study for the treatment of malignant brain tumors in childhood): accuracy and acute toxicity of the irradiation of the craniospinal axis. Results of the quality assurance program. Strahlenther Onkol. 1999;175:162–9.
Taylor RE, Bailey CC, Robinson K et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 Study. J Clin Oncol. 2003;21:1581–91.
Chang CH, Housepian EM, Herbert C Jr. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 1969;93:1351–9.
Evans AE, Jenkin RD, Sposto R et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg. 1990;72:572–82.
Corn BW, Yousem DM, Scott CB et al. White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02). Cancer 1994;74:2828–35.
Crossen JR, Garwood D, Glatstein E, Neuwelt EA. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol. 1994;12:627–42.
Kumar AJ, Leeds NE, Fuller GN et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000;217:377–84.
Klein M, Heimans JJ, Aaronson NK et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360:1361–8.
Gregor A, Cull A, Traynor E et al. Neuropsychometric evaluation of long-term survivors of adult brain tumours: relationship with tumour and treatment parameters. Radiother Oncol. 1996;41:55–9.
Brandes AA, Pasetto LM, Lumachi F, Monfardini S. Endocrine dysfunctions in patients treated for brain tumors: incidence and guidelines for management. J Neurooncol. 2000;47:85–92.
MacDonald TJ, Brown KM, LaFleur B et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet. 2001;29:143–52.
Packer RJ, Sutton LN, Goldwein JW, Perilongo G, Bunin G, Ryan J, et al. Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma. J Neurosurg 1991;74:433–440.
Farwell JR, Flannery JT. Adult occurrence of medulloblastoma. Acta Neurochir (Wien) 1987;86:1–5.
Peterson K, Walker RW. Medulloblastoma/primitive neuroectodermal tumor in 45 adults. Neurology 1995;45:440–442.
Giordana MT, Cavalla P, Chio A, Marino S, Soffietti R, Vigliani MC, et al. Prognostic factors in adult medulloblastoma. A clinico-pathologic study. Tumori 1995;81:338–346.
Giordana MT, Schiffer P, Lanotte M, Girardi P, Chio A. Epidemiology of adult medulloblastoma. Int J Cancer 1999;80:689–692.
Coulbois S, Civit T, Grignon Y, Taillandier L, Girard F, Marchal C, et al. [Adult medulloblastoma. Review of 22 patients]. Neurochirurgie 2001;47:6–12.
Louis E, Chinot O, Honnorat J, Broet Ph, Delattre JY, Tailandier L. Which optimal treatment of adult medulloblastoma? The ANOCEF group experience: retrospective study of 72 cases. J Neurooncol 2002;4 Suppl 1:258.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Brandes, A.A., Franceschi, E. (2011). Medulloblastomas. In: Norden, A., Reardon, D., Wen, P. (eds) Primary Central Nervous System Tumors. Current Clinical Oncology. Humana Press. https://doi.org/10.1007/978-1-60761-166-0_18
Download citation
DOI: https://doi.org/10.1007/978-1-60761-166-0_18
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-165-3
Online ISBN: 978-1-60761-166-0
eBook Packages: MedicineMedicine (R0)